Rebio Bio-B(06938.HK): Anders Gabrielsen appointed as Chief Medical Officer

NightAirdropper · 2026-03-27T21:39:15+00:00

Rebio Bio-B announces the appointment of Anders Gabrielsen as Chief Medical Officer and John Taylor as Chief Business Officer. Meanwhile, Gan Liming will continue to serve as Executive Director and in other roles. The changes will take effect from March 25, 2026.

NightAirdropper

2026-03-27 21:39:15

Abstract generation in progress

Gelonghui, March 25 | Reborn Biopharma-B (06938.HK) announced that the board of directors is pleased to announce: (i) Anders Gabrielsen has been appointed as the Chief Medical Officer of the company, responsible for the overall clinical development, medical affairs, and regulatory compliance; (2) John Taylor has been appointed as the Chief Business Officer of the company, responsible for the overall business development, licensing, and external collaboration as well as strategic investments; and (3) Gan Liming will no longer serve as the Chief Medical Officer but will continue as the company’s Executive Director, Co-CEO, and Global Head of R&D, effective from March 25, 2026.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes